This site is intended for healthcare professionals

FDA grants accelerated approval for Truseltiq to treat metastatic cholangiocarcinoma with an FGFR2 fusion - BridgeBio Pharma, QED Therapeutics and Helsinn Group.

Read time: 1 mins
Last updated:4th Jun 2021
Published:5th Jun 2021
The FDA has approved Truseltiq (infigratinib) for patients with previously-treated locally advanced or metastatic cholangiocarcinoma (CCA) with an FGFR2 fusion or rearrangement.
Condition: Cholangiocarcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest